Skip to Main Content

Flagship Pioneering is gearing up to launch a new company that seems to be developing precisely targeted treatments for neurodegenerative conditions, including Parkinson’s.

The new startup, dubbed Vesalius Therapeutics, will be led by Chris Austin, a high-profile recent Flagship recruit who was the founding director of the NIH’s National Center for Advancing Translational Sciences and a senior adviser to the National Human Genome Research Institute. Neurodegenerative conditions are one of his scientific areas of expertise.


Austin first described himself as CEO of Vesalius in October, according to public records reviewed by STAT. This will be his first Flagship company since joining the Cambridge, Mass.-based firm in March 2021. Austin also previously worked at Merck, researching new targets and treatments for schizophrenia and Alzheimer’s.

Get unlimited access to award-winning journalism and exclusive events.


Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!

To submit a correction request, please visit our Contact Us page.